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Analysis of the genetic basis of 
periodic fever with aphthous 
stomatitis, pharyngitis, and 
cervical adenitis (PFAPA) syndrome
Silvio Alessandro Di Gioia1, Nicola Bedoni1, Annette von Scheven-Gête2, Federica Vanoni2, 
Andrea Superti-Furga3, Michaël Hofer2, 4, * & Carlo Rivolta1, *
PFAPA syndrome is the most common autoinflammatory syndrome in children from Western 
countries. In spite of its strong familial clustering, its genetic basis and inheritance pattern are still 
unknown. We performed a comprehensive genetic study on 68 individuals from 14 families. Linkage 
analysis suggested a susceptibility locus on chromosome 8, but direct molecular sequencing did 
not support this initial statistical finding. Exome sequencing revealed the absence of any gene that 
was mutated in all patients. Exhaustive screening of genes involved in other autoinflammatory 
syndromes or encoding components of the human inflammasome showed no DNA variants that 
could be linked to PFAPA molecular pathology. Among these, the previously-reported missense 
mutation V198M in the NLRP3 gene was clearly shown not to co-segregate with PFAPA. Our results 
on this relatively large cohort indicate that PFAPA syndrome is unlikely to be a monogenic condition. 
Moreover, none of the several genes known to be involved in inflammation or in autoinflammatory 
disorders seem to be relevant, alone, to its etiology, suggesting that PFAPA results from oligogenic 
or complex inheritance of variants in multiple disease genes and/or non-genetic factors.
Autoinflammatory syndromes (AIS) are a group of disorders characterized by attacks of inflam-
mation that are not associated with the identification of autoreactive lymphocytes or of an external 
inflammation-triggering agent1. The majority of these syndromes are inherited as Mendelian traits, 
although a strong environmental influence has also been suggested for some forms2. Genes involved in 
AIS are linked to the inflammatory activation pathway and in particular to the activation of interleukin 
1β (IL1β)3.
Periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome belongs 
to the AIS group, although the etiology of this disease is still unknown. Described for the first time by 
Marshall in 19874, it is characterized by high fever (higher than 39 °C) lasting three to seven days and 
reoccurring regularly every three to eight weeks, alongside with at least one of these other symptoms: 
aphthous stomatitis, pharyngitis, or cervical adenitis5. It is an early-onset disease (usually before the age 
of 5 years) and in general it completely resolves before adulthood. However, cases of PFAPA that were 
persistent after adolescence have also been reported6–9. Patients are asymptomatic between episodes and 
have no developmental or growth problems. During PFAPA febrile attacks, an increase of IL1β cytokines 
has been shown both at the gene10 and protein levels11, suggesting the involvement of IL1β release in the 
etiology of the disease.
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The genetic origins of PFAPA are one of the most debated features of this syndrome. Although it is 
generally considered a sporadic disease12, familial clustering has been observed, suggesting the presence 
of  a possible hereditary component13. It is not unusual to ascertain families having more than one mem-
ber affected with PFAPA14,15, and positive family history for recurrent fevers can be detected in about 
half of PFAPA patients16. Several studies have investigated a possible involvement of the genes responsi-
ble for Familiar Mediterranean Fever (FMF, gene MEFV), TNF-Receptor Associated Periodic Syndrome 
(TRAPS, gene TNFRSF1A) Hyper IgD Syndrome (HIDS, gene MVK) and Cryopyrin Associated Periodic 
Syndrome (CAPS, gene NLRP3) in PFAPA cohorts11,17–21. An interesting hypothesis is that PFAPA could 
represent an unspecific, milder form of other AIS for which DNA variants in known AIS genes and 
present in the general population could be involved. An example is the NLRP3 variant V198M (or, more 
precisely, p.V200M, rs121908147), detected in the control population with an allele frequency of ~1%, 
and reported as a causative mutation for CAPS22, as well as to be associated with milder diseases or with 
other unspecified AIS23–25. V198M was also identified in PFAPA patients, suggesting a possible role of 
NLRP3 hypomorphic alleles in the pathogenesis of the disease11, although a clear genotype-phenotype 
association is still missing. Recently, a heterozygous deletion of the gene SPAG7 consequent to a chromo-
somal translocation was reported in a single individual affected with PFAPA and displaying other syn-
dromic features such as growth retardation, facial dysmorphisms, and dysplastic brachymesophalangy26, 
However, these data could not be replicated and it is currently not clear whether the link between SPAG7 
and PFAPA is causal or coincidental.
In this work, we perform for the first time an unbiased, comprehensive genetic analysis on a collection 
of families with PFAPA syndrome. Our data indicate that PFAPA is neither a monogenic disease nor a 
condition that can be clearly associated with DNA changes in other AIS genes. In addition, we demon-
strate that the NLRP3 DNA variant V198M is not associated with this disease.
Results
PFAPA syndrome shows an apparent autosomal dominant with incomplete penetrance pat-
tern of inheritance, if considered as a Mendelian disease. We analyzed 68 individuals from 
14 families segregating PFAPA by genome-wide SNP genotyping, whole-exome sequencing, or both. 
Pedigree analysis suggested clear inheritance, compatible with an autosomal dominant with incomplete 
penetrance model, if Mendelian inheritance with no genetic heterogeneity is assumed as a model (Fig. 1). 
Because of the lack of genetic data for this disease to infer the penetrance factor from the literature, we 
empirically set it to be around 50% following pedigree examination. Following these observations, we 
decided to perform a genome-wide linkage analysis to identify a possible locus carrying the causative 
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Figure 1. Families analyzed. Alphanumeric codes indicate individuals who were investigated by genome-
wide SNP genotyping, while arrows indicate individuals whose DNA was processed by exome sequencing 
(some individuals were analyzed by both techniques). Boxes indicate families that underwent linkage studies.
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gene of PFAPA syndrome. We selected a subset of informative families (families A, B, C, H, K, L, O) based 
on their clinical information. Multifamily whole genome analysis considering non-parametric methods 
revealed a single and unique peak on chromosome 8 with a maximum LOD score of 2.9 (Fig. 2a). This 
peak was also conserved with a parametric method by considering a fully penetrant inheritance pattern 
with a LOD score of 3.4 (Fig.  2b). The identified region was of 11 Mb and spanned bands 8q21.1 to 
8q24.4 of chromosome 8 (Fig. 2c). This region is scarcely populated, as it contains only 40 RefSeq genes, 
of which only 32 were protein coding (Fig.  2d – and Supplementary Table 1). We selected 3 affected 
individuals (B1, L1 and C2) to be screened for all exons of all genes that are present in the interval. 
Analysis of DNA variants failed to reveal any single gene that was mutated in all three affected individ-
uals within the identified region, with the exception of two non-coding variants representing common 
polymorphisms (Supplementary Table 2).
Exome capture and NGS show no common disease gene associated with PFAPA. Despite 
the negative results from the screening of the chromosome interval, we could not completely exclude 
a priori a monogenic model of inheritance. Therefore we decided to select some key individuals to be 
whole-exome sequenced. Inclusion criteria were the availability and the quality of the extracted DNA, as 
well as the size and the quality of the clinical information regarding the family (Table 1). We sequenced, 
whenever possible, two affected individuals within the same family, or one obligated carrier and a patient, 
for a total of 11 disease-carrying subjects and one unaffected family member (Fig. 1, arrows).
Under the hypothesis that PFAPA is a monogenic condition with no genetic heterogeneity, we 
scanned the list of DNA variants present in all patients, in order to identify a gene carrying rare variants 
(minor allele frequency, or MAF < 2%) in more than 90% of the analyzed samples (to allow the presence 
of false negatives). In total, we detected 14 genes that satisfied these criteria (Table  2). Four of them 
belonged to the MUC family and represented false positives results, similar to those obtained by other 
exome sequencing projects27. The same was true for mutations in six other genes (WNK1, ZNF384, TTN, 
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Figure 2. Linkage analysis of PFAPA families. a) Output of Merlin linkage analysis for linear (black line) 
and exponential (blue line) non-parametric models. For our study, the exponential model gives a better 
resolution, since it is indicated for a small number of families and large allelic sharing. b) Output for a 
parametric model (autosomal dominant with incomplete penetrance). The peak at chromosome 8 is still 
conserved. c) Location of the linkage interval on the long arm of chromosome 8, between markers rs221160 
and rs221962. d) Protein coding genes present in the identified interval.
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GOLGAL6L1, C11orf40, and KIAA1751) that, for various reasons, could be recognized as sequencing 
artifacts28. The remaining four genes (NBPF15, OR4C45, ZNF492, and PCMTD1) had many novel var-
iants, which were however also present in controls. No common gene carrying rare variants that could 
be compatible with pathogenic mutations could therefore be identified in our cohort.
No rare or potentially abnormal DNA variants were found in the SPAG7 gene, in any of the patients analyzed.
Screening for mutations in genes for autoinflammatory recurrent fever conditions does 
not support their involvement in PFAPA etiology. Since the presence of rare variants in other 
Patient*
Age at onset 
(months) m/f
Major 
symptoms
Other 
symptoms Positive FH
A1 54 f P Brother A2: PFAPA
A2 60 m P AbdP, D Sister A1: PFAPA
B1 6 f AD Cousin: PFAPA
F1 12 m AD AbdP, H
O1 41 f APH AbdP
R1 26 f P, AD AR
PLA 6209 18 f P, AD, APH Both parents: TE, Father: recurrent P
PLA 6509 4 m P, AD AbdP Both parents: TE
PLA 5008 16 m P, AD, APH Father: TE
Table 1.  Clinical characterization of patients analyzed by whole exome sequencing. FH: family history, 
P: pharyngitis, AD: adenitis, APH: oral aphtosis, AbdP: abdominal pain, M: myalgia, AR: arthralgia, R: rash, 
H: headache, D: diarrhea, TE: tonsillectomy. *Individuals O5, and R2 were not affected and thus were not 
examined. Individual B7 was not available for examination.
Gene name
Number 
of 
variants
Cases 
carrying 
one or 
more 
variants Exclusion criteria
WNK1 54 100% Alignment mistake
MUC6 40 100% Mucin gene
MUC2 19 100% Mucin gene
NBPF15 11 100%
Many novel variants, 
also present in 
controls
ZNF384 1 100% Bad reference
OR4C45 1 100%
Many novel variants, 
also present in 
controls
MUC17 91 90% Mucin gene
MUC16 26 90% Mucin gene
TTN 18 90% Low coverage regions
ZNF492/ZNF98 16 90%
Many novel variants, 
also present in 
controls
GOGAL6L1 14 90% Not well annotated gene
PCMTD1 8 90%
Many novel variants, 
also present in 
controls
C11orf40 3 90%
Suspected false 
positive change in 
dbSNP
KIAA1751 2 90%
Suspected false 
positive change in 
dbSNP
Table 2.  Variant-carrying genes that were common to all affected individuals.
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inflammatory genes could have an impact on the PFAFA phenotype, we decided to search specifically for 
variants in all known autoinflammatory genes in our cohort (Supplementary Table 3). Screening of the 
MEFV gene, associated with FMF, revealed the presence of polymorphisms in heterozygous state with 
unknown function for patients O1 (p.I591T, rs11466045, MAF 0.07) and R1 (p.F425Y, rs11466045, MAF 
0.001). None of these were present in the other analyzed members of the family. Conversely, in family 
A, we identified a variant (p.E148Q, rs3732930, MAF 0.06) shared among the two affected individuals. 
Interestingly, both patients of family A also carried a heterozygous change in NLRP3 related to CAPS 
(p.Q703K, rs35829419, MAF 0.04). In family B, we identified a rare variant in the gene TNFRSF1A, usu-
ally associated with milder forms of TRAPS (p.R121Q, rs4149584, MAF 0.018). This change cosegregated 
with the disease. We also identified a novel change in the gene NLRP12, associated with familial cold 
autoinflammatory syndrome-2, in patient R1 (p.R211C). This change, located in a well-conserved region 
of the protein (Table 3), was also present in R1’s unaffected sister.
The NLRP3 variant p.V198M associated with CAPS does not cosegregate with PFAPA affected 
status. Analysis of NLRP3 in family O revealed the presence of the variant V198M (p.V200M, 
rs12908147, MAF 0.01), often associated with milder forms of CAPS23,29. This variant was found in 
heterozygous state only in the obligated carrier member O5, whereas it was not present in the proband. 
Cosegregation analysis on available members of the family revealed that this change is present also in 
the two healthy siblings and it is absent in the affected one, confirming that this change is not involved 
in the etiology of PFAPA in this family (Fig. 3).
Several rare variants with uncertain function were present in inflammasome-related 
genes. Since an impairment in IL-1β and NF-κB signaling and production has been reported in 
individuals with PFAPA syndrome10, we decided to look closely at all known genes belonging to the 
inflammasome complex, with particular attention to genes involved in the production of mature IL-1β. 
All identified variants in these genes are listed in Table 3. We identified two non-annotated changes in 
NLRP5, for patients 2940 and F1 (p.R274Q, and p.N255S, respectively). Again, patient 2940 presented 
another rare variant in the gene NLRP2, p.L607P (rs182098487, MAF 0.001). A novel change, p.G504D, 
was found in this same gene in patient B7, although it was not found in the affected cousin. Among 
GENE rs number Samples AA change MAF Domain
IPAF (NLRC4) 149451729 2941 p.G786V 0.004 LRR6
NAIP 61757629 B7 p.A161T 0.02 BIR2
NLRP1 61754791 2942 p.V939M 0.02 LLR5
NLRP2 142463014 2942 p.S4L 0.01 DAPIN
novel B7 p.G504D 0 NACHT
182098487 2940 p.L607P 0.005 between NACHT and LRR1
NLRP3 121908147 O5 p.V198M 0.01 between DAPIN and NACHT
35829419 A1,A2 p.Q703K 0.05 between NACHT and LRR1
NLRP4 117212164 O1,O5 p.T162M 0.004 NACHT
NLRP5 novel F1 p.N255S 0.001 between DAPIN and NACHT
novel 2940 p.R274Q 0.001 between DAPIN and NACHT
NLRP10 150112481 O1 p.I384T 0.001 NACHT
NLRP11 11671248 2940 p.S1025L 0.01 C-terminal
NLRP12 novel R1,R2 p.R211C 0.001 NACHT
NOD1 (CARD4) novel 2942 p.C241G 0 NACHT
NOD3 (NLRC3) novel 2940 p.R1005Q 0 LRR15
NOD4 16965150 2941, F1 p.S210L 0.03 before NACHT domain
NOD5 (NLRX1) 150153921 B7 p.L193V 0.007 NACHT
145779362 O1,O5 p.R547W 0.007 between NACHT and LRR1
NWD1 149694092 F1 p.S306L 0.006 between WD and NACHT
Table 3.  Variants in NLR and inflammasome-related genes, and protein domains affected by them. AA: 
amino acid, MAF: minor allele frequency.
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the Nod-Like Receptor genes, NLRP2 showed the highest number of variants within PFAPA subjects, 
but these were also rather common in the control CoLaus Lausanne cohort (p.S4L, rs142463014, for 
2492, MAF 0.09; p.I331V, rs61735077, for R1 and R2, MAF 0.05). Another common variant in NLRP4 
was p.T162M (rs117212164, MAF 0.03), co-segregating with the condition in family O and affecting a 
conserved residue in the NACHT domain of the NLRP4 protein. Among other genes from the NLR 
families we identified a rare change in NLRP10, p.I384T (rs150112481, MAF 0.01) although only in 
patient O1, and the change p.S1025L (rs11671248, MAF 0.08) in NLRP11 in patient 2940. Not many rare 
variants were identified in the coding region of the NLRP1 gene, with the only exception being p.V939M 
(rs61754791, MAF 0.01), found only in patient 2942. Interestingly, however, both patient 2941 and family 
R shared a rare haplotype composed by different missense polymorphisms located at the C-terminal 
of the protein (Fig.  4). A similar haplotype has been recently associated with an impairment of IL-1β 
processing by the inflammasome. Common polymorphisms in CARD8 were found in a heterozygous 
state in our cohort and these have been previously associated with other defects of the inflammatory 
system. These polymorphisms were p.C10X (rs2043211, MAF 0.30) found in patients A1, B7, F1, 2940 
and p.V148fs (rs140826611, MAF 0.06) in A2, F1, 2941 and 2942. Among other inflammasome genes, 
we identified a heterozygous missense change in NLRC4, better known as IPAF, p.G786V (rs149451729, 
MAF 0.03) in patient 2941; a novel change in NOD1 (p.C241G) in patient 2942, again in the NACHT 
domain of this protein. A summary of all analyzed variants identified in inflammasome genes and their 
affected functional domain is reported (Table 3).
O5 O4
O2 O3O1
Figure 3. Cosegregation analysis for the V198M variant in NLRP3, in family O. Variant V198M 
(p.V200M) in gene NLRP3 does not cosegregate with PFAPA in this pedigree (healthy members carry 
it, whereas the affected member does not), suggesting that this polymorphism is not associated with the 
disease.
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Figure 4. Graphical representation of the haplotype identified on NLRP1 for two subjects. The gene 
structure is depicted in the upper part. Amino acid changes identified in these individuals are reported. All 
these changes have a MAF of <0.1. PYD: pyrin domain; NACHT: Conserved NAIP, CIITA, HET-E and TP-1 
domains; LRR: leucine rich receptor domain; CARD: Caspase activator and recruitment domain.
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Discussion
PFAPA is a common auto-inflammatory disease with an overall good prognosis. Regular PFAPA fever 
flares have a significant impact on the quality of life of the patients and their families and are interfer-
ing with regular school attendance and normal daily activities. The delay to diagnosis may represent 
several months or years and children may be exposed to unnecessary diagnostic procedures. A better 
understanding of the pathogenesis of this disease would lead to more specific diagnostic tools and might 
relieve the suffering of patients and their families. Clearly the pathogenesis of the disease is linked to the 
immune system, but no convincing information about the etiology and in particular about the genetic 
basis of PFAPA has been obtained so far.
In our clinical practice, we identified a number of families for which PFAPA seems to have a genetic 
basis. Based on pedigrees analysis, we could infer an autosomal dominant model of inheritance, with a 
penetrance factor of almost 50%. However, some families showed an apparently dominant inheritance 
with full penetrance (e.g. family K), whereas for others a recessive status could not be excluded a priori 
(e.g. family F). According to these observations, we selected the seven most informative families of our 
collection to perform a genome-wide linkage study. This analysis revealed a clear peak on the long arm of 
chromosome 8, notably between 8q24.1 and 8q24.3. This region contained a small number of genes and 
was very close to the telomere of chromosome 8. The significance of the identified area was confirmed 
using non-parametric analysis, and by comparing haplotypes of affected individuals against non-affected 
ones. Interestingly, the identified region contained several lncRNAs and many miRNAs, as well as other 
unknown genes or genes without a clear function. Based on these data we therefore performed a custom 
sequence capture of all known exons for genes in the interval. The custom capture chip was designed 
based on annotation of build hg35.1 of the human genome. This implies that we could have missed some 
recently discovered genes, and all the hypothetical genes and lncRNAs that corresponded to the majority 
of elements annotated in the locus. The sequencing did not reveal any single mutated gene shared by all 
affected individuals.
To exclude the possibility that we did not detect a causative disease gene because of inconsistencies 
in the inferred inheritance pattern, we decided to sequence the entire exome of 11 affected individuals, 
one “obligate carrier” (i.e. a healthy individual connecting two branches of a pedigree with affected sub-
jects), and one unaffected family member. Our analyses revealed the absence of a unique gene that was 
mutated in all the affected individuals, including genes and noncoding RNAs lying in the critical region 
on chromosome 8. Although we cannot exclude a priori that mutations that escape exome sequencing 
such as intronic variants and copy number variations could be the cause of the disease, our data disfavor 
genetic homogeneity for PFAPA. 
We then decided to investigate the possibility that mild mutations or rare variants in other known 
autoinflammatory genes could cause the PFAPA phenotype. This hypothesis is currently a matter of 
debate, since the diagnosis of milder forms of autoinflammatory disease and PFAPA is often overlapping, 
leading to diagnostic uncertainties. In particular, low-frequency polymorphisms (common in 1-4% of 
the healthy population) have been associated with PFAPA or milder forms of autoinflammatory diseases, 
mostly because no other strong changes in candidate genes were identified17,19,30. Our analysis revealed 
that, although we identified a few rare missense changes in some inflammatory genes, the frequencies of 
these variants were not different from those that were present in the general population, indicating that 
they may not be sufficient to induce the disease. Moreover, some of these changes did not co-segregate 
with the phenotype, or were also present in healthy members of the family. This was for example observed 
for the NLRP3 variant V198M (p.V200M). This change has been reported in several different forms of 
NLRP3-associated syndrome, such as classical CAPS22,23,29, or other autoinflammatory manifestation24,31, 
although it is classified as a low penetrant mutation, due to the fact that it is present in a number of 
healthy carriers (in the Lausanne control population it is present with a frequency of about 1%). The role 
of this variant is still debated, but it is regrettably reported as a bona fide pathogenic mutation in medical 
genetics diagnostic protocols. The presence of this variant only in the unaffected individuals of family O 
strongly contradicts its possible role in generating an inflammatory phenotype. A recent paper, probably 
the most complete clinical study of V198M, showed that 19 cases of CAPS out of 830 carried V198M, 
although 3 of these harbored other possible candidates in other inflammatory genes, and V198M was 
present in 7 asymptomatic individuals related to these 19 patients25. Furthermore, Valine at codon 200 is 
not at all conserved through evolution, suggesting that this amino acid residue is likely not detrimental 
for protein function. Other mammals such as rat, dog and mouse carry a methionine at the same posi-
tion of their natural NLRP3 orthologues. Altogether, these data indicate that V198M (p.V200M) is likely 
a neutral human polymorphism and that patients carrying this variant should probably be re-analyzed 
for other causative mutations.
Another example is the novel change found in patient R1, the NLRP12 p.R211C, which is present 
in a well-conserved domain and has a predicted strong impact on protein function. Recently a similar 
missense mutation (p.R352C) in the same NACHT domain of this gene was associated with genetically 
unexplained periodic fevers32, with a PFAPA-like phenotype, and was shown to cause a functional defect 
in Caspase-1 signaling. The fact that R1’s unaffected sister carries this allele likely indicates that this 
change has no effects (or has at best a hypomorphic role) at the clinical level. It is interesting to notice 
that the affected patient (R1) also carried another very rare change in the gene MEFV (p.F425Y) with 
function unknown. The intriguing hypothesis of digenic or multigenic mutations causing the impairment 
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of the inflammasome seemed to be reinforced by the identification of two polymorphisms often associ-
ated with the disease in family A. More specifically, we identified a change in the MEFV gene (p.E148Q) 
and in NLRP3 (p.Q703K), both common polymorphisms with a possible functional effect on the pro-
tein. In particular, for p.Q703K, functional impairment of NLRP3 has been clearly demonstrated33. 
Unfortunately this digenic pattern of inheritance was not identified in other affected subjects within 
known autoinflammatory-associated genes34. Nevertheless we cannot exclude, based on this observa-
tion, that other rare variants present in other inflammasome-associated genes could be involved in the 
etiology of PFAPA.
To investigate this possibility we carefully screened some of the genes that compose the inflammasome 
set (in particular the NLR family members), based on current literature35–37. We identified a few novel var-
iants in NLRP2, NLRP5 and NOD1, as well as some very rare variants in other inflammasome-associated 
genes, such as NLRP10, NLRP4, NLRP11 and NLRC4. Interestingly, the majority of these genes were 
involved in IL-1β inflammasome activation, or in the NF-κB pathway. For example, new evidence 
demonstrated the high similarity and redundancy across the structure of NLRP1, NLRP6, NLRP10, 
NLRP3 and NLRP1238. Although the function within the inflammasome for many of these members has 
not yet been clarified, structural similarities among NLRs suggest that all these components could some-
how mediate inflammation in response to different stimuli and trigger IL-1β production37. Moreover, we 
identified two samples carrying a specific rare haplotype in NLRP1 that has recently been associated with 
vitiligo and autoimmune diseases, and connected to an increase of IL-1β release in patients carrying the 
haplotype39. Dominant mutations in the same gene have been shown to cause systemic inflammation 
in mouse models40. Another observation from the analysis on the possible effect on protein structure 
was that the majority of identified variants seemed to be present in or in proximity of the NACHT 
domain. This domain has an ATPase activity and is crucial for the self-oligomerization (usually to form 
heptamers or hexamers) of NLRs to form the structure necessary for inflammasome assembly41. NACHT 
domain mutations have been associated with structural changes that lead to a continuous activation of 
the inflammasome complex. A link between mutations affecting NACHT and different autoinflamma-
tory diseases has been observed in NLRP3 and NOD1 for example42,43, reinforcing the hypothesis of a 
gain-of-function effect of these mutations on the formation of the complex.
It is interesting to observe that every single affected individual in this cohort presented more than one 
rare variant in one of the inflammasome-composing genes. Unfortunately, due to large number of genes 
involved, it is impossible to perform a meaningful statistical analysis based on this observation, unless 
extremely large groups of PFAPA patients are recruited and analyzed, possibly as part of an extended 
international effort. However, it may not be unreasonable to start thinking of a “total inflammatory 
burden” similar to the concept of “total ciliary burden” proposed for disease such as the Bardet-Biedl 
syndrome, that has developed from a simple Mendelian disorder into a trigenic44,45 and finally into an 
oligogenic disorder46.
In conclusion, the absence of a common gene harboring exonic mutations in all the affected individu-
als analyzed in this work suggests that PFAPA syndrome is transmitted either as Mendelian disease with 
high genetic heterogeneity, or as an oligogenic or complex trait. Mutations in noncoding or poorly cov-
ered regions of the genome that may have escaped our analysis are also possible, and further studies are 
needed to assess their potential presence in PFAPA patients. Oligogenic inheritance would be consistent 
with our observation that affected individuals may harbor multiple variants in inflammasome-associated 
genes. However, given the fact that such variants may be shared with a significant number of the general 
unaffected population, specific studies are needed to underpin or refute this hypothesis, and extreme 
caution should be used prior to indicating causality.
Methods
Patient selection and ethical commitment. The families participating in this study were from a 
large collection of PFAPA patients who were ascertained at the Center for Pediatric Rheumatology of 
Western Switzerland at the Lausanne University Hospital and the Geneva University Hospital. The famil-
ial clustering and inheritance patterns were investigated by administrating a specific survey to family 
members of the affected patients. The diagnosis of PFAPA in family members was based on the report, 
by the affected persons or their parents, of a stereotypical and recurrent pattern of illness during their 
own childhood. The PFAPA phenotype was defined according to previously published clinical criteria47; 
in addition a genetic screening for one or more monogenic periodic fever syndromes (FMF, TRAPS, 
HIDS) was performed for selected individuals. Our study was designed in accordance with the tenets 
of the declaration on Helsinki and was approved by the Institutional Review Boards of the University 
of Lausanne and of the Lausanne University Hospital. Written informed consent was obtained from all 
patients who enrolled in the study. As controls for the screening of rare variants, data obtained by exome 
sequencing of 416 healthy anonymous individuals from a large population-based study done in Lausanne 
(the CoLaus cohort) were used48.
DNA extraction and lymphocytes immortalization. DNA was extracted from peripheral leu-
kocytes (PBLs) of participants by using the NucleonBaCC3 DNA extraction kit (GE healthcare, Life 
Science). For some family members and for all probands, white mononucleate cells were isolated using 
Ficoll-Paque PLUS (GE healthcare Life Science), according to the manufacturer’s instruction. Once 
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isolated, cells were processed for EBV immortalization using classical protocols49, optimized for our 
requirements as follows. After three washes with PBS and 2% FCS, 1 × 106 PBL cells were transferred 
to a 10 ml Falcon tube, diluted in 1 ml of LCC medium (RPMI 1640 medium, 20% serum, 2 μg/ml 
Cyclosporine A) and incubated with a EBV virus suspension for 1 h. Cells were then plated into single 
wells from a 12-well plate and kept in culture for ~1 month. Following this immortalization process, cells 
were frozen in RPMI 1640 with 20% serum and 10% DMSO for cryopreservation.
Genotyping and linkage analysis. Six out of 14 families were selected for whole genome genotyp-
ing, based on the availability of clinical information and the size of the family trees. DNA from all avail-
able members of each of these families was assessed by the Illumina Human Linkage12 array (Illumina, 
CA), containing more than 6000 highly heterozygous SNPs, with an average distance between SNPs of 
about 441 kb. Output was then analyzed using the Genotype Studio software (Illumina Inc., CA) and 
the SNPs calls were filtered based on quality and the presence of Mendelian inconsistencies. Genotype 
data were handled using the commercial software Progeny 7 (Progeny Software LLC) to generate appro-
priates files for linkage analysis software, carried out with the Merlin package and by using the Vital-IT 
high performance computer structure (the Swiss Institute of Bioinformatics, Lausanne, www.vital-it.ch). 
Both parametric and not-parametric analysis models were tested. Because of the lack of data on genetic 
background for this disease, we could not perform a classical computational approach to estimate the 
penetrance factor for the parametric analysis. Therefore, penetrance factor for parametric analysis was 
empirically calculated based on the observed families as a ratio between the number of affected patients 
and the total number of subjects predicted to be affected based on the model.
Next generation sequencing. In the first sequencing experiment, aimed at determining DNA vari-
ants on chromosome 8 interval, a custom made sequence capture chip, based on Agilent SureSelect tech-
nology, was designed by Genotypic (Bangalore, India). Captured DNA was then sequenced by Fasteris 
(Geneva, Switzerland) by using a single lane of the Illumina Genome Analyzer II (Illumina, San Diego 
CA).
For exomes, the entire capturing and sequencing procedures were performed at the Lausanne Genomic 
Facility (GTF). Genomic DNA samples were barcoded and exons were captured using the SureSelect 
Exome kit V5 (Agilent, Santa Clara, CA) according to the manufacturer’s protocols. Sequencing was 
performed using again a single lane of the Illumina Genome Analyzer II (Illumina, San Diego, CA). 
Reads were aligned to the reference sequence (human genome reference 19 – hg19) using Novoalign 2.08 
(Novocraft.com). The obtained coverage was 10x or higher for 92% of the targeted regions. Base quality 
score recalibration, indel realignment, duplicates removal and SNP and INDEL calling were performed 
by using Genome Analysis Tools kit (GATK)50. Variant annotation and filtering was performed with 
both Annovar51 and the Ingenuity Variant Analyzer web interface (Ingenuity System, CA). A subset of 
the identified variants were confirmed and analyzed by classical Sanger sequencing according standard 
protocols. Statistical analysis on rare variants present in inflammasome related genes was performed 
using the Graphpad on-line calculator (http://graphpad.com). A two-tails χ2 test adjusted for 2 × 2 con-
tingency table was used.
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